Literature DB >> 18556643

Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation.

John S Sampalis1, Joanne Langley, Xavier Carbonell-Estrany, Bosco Paes, Karel O'Brien, Upton Allen, Ian Mitchell, José Figueras Aloy, Carmen Pedraz, Andrea F Michaliszyn.   

Abstract

OBJECTIVE: The purpose of the study was to develop and validate a clinical instrument predicting the risk of respiratory syncytial virus (RSV)-associated hospitalization (RSV-H) in premature infants born at 33 through 35 completed weeks of gestation (33-35GA).
DESIGN: An RSV risk scoring tool (RSV-RS) was developed by entering risk factors for RSV-H, determined in a Canadian prospective study, into a multiple logistic regression model. The scoring tool was then validated externally with data from a Spanish case-control study (FLIP). The Canadian cohort comprised 1758 RSV-positive infants born 33-35GA, of whom 66 (3.7%) had confirmed RSV-H. The FLIP data set comprised 186 (33.4%) RSV-H cases and 371 (66.7%) controls.
METHOD: The primary outcome measure was RSV-H. The RSV-RS score was the sum of the weighted probabilities for each included risk factor multiplied by 100 and ranged from 0 to 100. Receiver operator characteristic curve analyses determined cutoff points to predict subjects at low, moderate, or high RSV-H risk.
RESULTS: The RSV-RS included 7 risk factors and cutoff scores of 0-48, 49-64, and 65- 100 for low-, moderate-, and high-risk subjects, respectively. For the Canadian cohort, RSV-RS sensitivity in predicting RSV-H cases was 68.2%, with 71.9% specificity. With the FLIP data set, the RSV-RS had lower accuracy (61.3% sensitivity; 65.8% specificity) but showed significant positive association with increased risk for RSV-H.
CONCLUSION: The RSV-RS accurately identified 33-35GA infants at increased risk for RSV-H in a Canadian cohort. External validation with Spanish case-control study data further confirmed that the scoring tool is appropriate for the estimation of RSV-H risk.

Entities:  

Mesh:

Year:  2008        PMID: 18556643     DOI: 10.1177/0272989X08315238

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  24 in total

1.  Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.

Authors:  Kelly A Smart; Krista L Lanctôt; Bosco A Paes
Journal:  Can Fam Physician       Date:  2010-10       Impact factor: 3.275

2.  Letters to the Editor.

Authors:  I Mitchell; B Paes; K Lanctot; Rupesh Chawla; Aaron Chiu; Marianna Mitchell; Cecil Ojah; April Price; Sandra Seigel; Amanda Symington
Journal:  Paediatr Child Health       Date:  2015 Nov-Dec       Impact factor: 2.253

3.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

4.  Respiratory syncytial virus and palivizumab: Where are we in 2014?

Authors:  Joan Robinson
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

5.  The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study.

Authors:  Michelle L Butt; Amanda Symington; Marianne Janes; Louann Elliott; Susan Steele; Bosco A Paes
Journal:  Eur J Pediatr       Date:  2010-12-22       Impact factor: 3.183

6.  Prevention of respiratory syncytial virus infection.

Authors:  L Samson
Journal:  Paediatr Child Health       Date:  2009-10       Impact factor: 2.253

7.  A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).

Authors:  B Paes; I Mitchell; A Li; K L Lanctôt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-01       Impact factor: 3.267

Review 8.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

9.  What risk factors for sudden infant death syndrome are preterm and term medically complex infants exposed to at home?

Authors:  Ian Mitchell; Daniel Y Wang; Christine Troskie; Lisa Loczy; Abby Li; Bosco Paes; Krista Lanctôt
Journal:  Paediatr Child Health       Date:  2020-06-15       Impact factor: 2.253

10.  Respiratory syncytial virus hospitalization and incurred morbidities the season after prophylaxis.

Authors:  Michelle L Butt; LouAnn Elliott; Bosco A Paes
Journal:  Paediatr Child Health       Date:  2018-04-14       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.